Oligoribonucleotide-Containing Nanocomplexes Based on Aminopropylsilanol Nanoparticles as Effective Inhibitors of Influenza A Virus Replication
-
Published:2023-12
Issue:4
Volume:78
Page:249-254
-
ISSN:0096-3925
-
Container-title:Moscow University Biological Sciences Bulletin
-
language:en
-
Short-container-title:Moscow Univ. Biol.Sci. Bull.
Author:
Repkova M. N.ORCID, Mazurkov O. Yu.ORCID, Filippova E. I.ORCID, Procenko M. A., Mazurkova N. A.ORCID, Chelobanov B. P.ORCID, Levina A. S.ORCID, Zarytova V. F.ORCID
Reference20 articles.
1. Chernikov, I.V., Vlassov, V.V., Chernolovskaya, E.L. Current development of siRNA bioconjugates: from research to the clinic. Front. Pharmacol. 2019, vol. 10, p. 444. 2. Fabrega, C., Aviñó, A., Navarro, N., Jorge, A.F., Grijalvo, S., Eritja, R. Lipid and peptide-oligonucleotide conjugates for therapeutic purposes: from simple hybrids to complex multifunctional assemblies. Pharmaceutics 2023, vol. 15, no. 2, p. 320. 3. Lim, S.A., Cox, A., Tung, M., Chung, E.J. Clinical progress of nanomedicine-based RNA therapies. Bioact. Mater. 2022, vol. 12, pp. 203–213. 4. Kanasty, R., Dorkin, J.R., Vegas, A., Anderson, D. Delivery materials for siRNA therapeutics. Nat. Mater. 2013, vol. 12, no. 11pp. 967–977. 5. Juliano, RL. The delivery of therapeutic oligonucleotides. Nucleic Acids Res. 2016, vol. 44, no. 14, pp. 6518–6548.
|
|